This lower genetic complexity of ALK-driven NSCLC compared to other lung tumors may explain why therapeutic progress has been much faster and survival gains much larger for ALK+ compared to other lung cancer patients. The gene discussed is ALK; the disease is non-small cell lung carcinoma.